JohnAnderson80 on Bluemong

$GSK US FDA Adcom Votes (3 Yes; 5 No) overall benefit-risk of belantamab mafodotin in combination with bortezomib and dexamethasone Is Not favorable at the proposed dosage in the proposed patient population - ODAC Meeting (GlaxoSmithKline plc)
(More at https://tradethenews.com/?...

5 months ago

No replys yet!

It seems that this publication does not yet have any comments. In order to respond to this publication from JohnAnderson80 , click on at the bottom under it

Sign in

No replys yet!